Skip to content
10-K

Annual Report

IGC Pharma, Inc. IGC

0001185185-25-000706

← back to feed
Filed
Jun 27, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Jun 20, 2025 83.89M sh
Shares Diluted FY 2025 · Mar 31, 2025 76.52M sh
Shares Diluted FY 2025 · Mar 31, 2024 58.84M sh
Capex FY 2025 · Mar 31, 2025 $112K
Capex FY 2025 · Mar 31, 2024 $138K
Operating Cash Flow FY 2025 · Mar 31, 2025 −$4.8M
Operating Cash Flow FY 2025 · Mar 31, 2024 −$5.2M
Long Term Debt FY 2025 · Mar 31, 2025 $134K
Long Term Debt FY 2025 · Mar 31, 2024 $137K
Short Term Debt FY 2025 · Mar 31, 2025 $3K
Short Term Debt FY 2025 · Mar 31, 2024 $3K
Cash And Equivalents FY 2025 · Mar 31, 2025 $405K
Cash And Equivalents FY 2025 · Mar 31, 2024 $1.2M
Stockholders Equity FY 2025 · Mar 31, 2025 $6.33M
Stockholders Equity FY 2025 · Mar 31, 2024 $7.32M
Stockholders Equity FY 2025 · Mar 31, 2023 $14.91M
Current Liabilities FY 2025 · Mar 31, 2025 $2.26M
Current Liabilities FY 2025 · Mar 31, 2024 $2.34M
Total Liabilities FY 2025 · Mar 31, 2025 $2.42M
Total Liabilities FY 2025 · Mar 31, 2024 $2.58M
Current Assets FY 2025 · Mar 31, 2025 $2.9M
Current Assets FY 2025 · Mar 31, 2024 $3.71M
Total Assets FY 2025 · Mar 31, 2025 $8.75M
Total Assets FY 2025 · Mar 31, 2024 $9.9M
Eps Diluted FY 2025 · Mar 31, 2025 −$0.09
Eps Diluted FY 2025 · Mar 31, 2024 −$0.22
Eps Basic FY 2025 · Mar 31, 2025 −$0.09
Eps Basic FY 2025 · Mar 31, 2024 −$0.22
Sga Expense FY 2025 · Mar 31, 2025 $4.41M
Sga Expense FY 2025 · Mar 31, 2024 $6.76M
Rd Expense FY 2025 · Mar 31, 2025 $3.66M
Rd Expense FY 2025 · Mar 31, 2024 $3.77M
Net Income FY 2025 · Mar 31, 2025 −$7.12M
Net Income FY 2025 · Mar 31, 2024 −$13M
Operating Income FY 2025 · Mar 31, 2025 −$7.45M
Operating Income FY 2025 · Mar 31, 2024 −$9.8M
Gross Profit FY 2025 · Mar 31, 2025 $619K
Gross Profit FY 2025 · Mar 31, 2024 $733K
Cost Of Revenue FY 2025 · Mar 31, 2025 $652K
Cost Of Revenue FY 2025 · Mar 31, 2024 $612K
Revenue FY 2025 · Mar 31, 2025 $1.27M
Revenue FY 2025 · Mar 31, 2024 $1.35M